Carlo Napolitano

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6053292/carlo-napolitano-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235 papers	26,469 citations	79 h-index	161 g-index
281 ext. papers	29,805 ext. citations	10 avg, IF	6.26 L-index

#	Paper	IF	Citations
235	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003391	5.2	0
234	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Blockers.. *JAMA Cardiology*, **2022**,	16.2	3
233	Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death. *Bioscience Reports*, **2021**, 41,	4.1	6
232	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. *Europace*, **2021**, 23, 147-148	3.9	18
231	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. *Genetics in Medicine*, **2021**, 23, 47-58	8.1	13
230	Cardiac ryanodine receptor calcium release deficiency syndrome. *Science Translational Medicine*, **2021**, 13,	17.5	18
229	Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy. *Heart Rhythm*, **2021**, 18, 1698-1706	6.7	0
228	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27
227	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. *Circulation*, **2020**, 142, 513-515	16.7	26
226	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. *Heart Rhythm*, **2020**, 17, 1456-1462	6.7	115
225	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. *Journal of the American College of Cardiology*, **2020**, 75, 1772-1784	15.1	18
224	Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?. *European Heart Journal*, **2020**, 41,	9.5	1
223	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the Gene Associated With Brugada Syndrome. *Frontiers in Physiology*, **2020**, 11, 616819	4.6	6
222	Supervised methods to extract clinical events from cardiology reports in Italian. *Journal of Biomedical Informatics*, **2019**, 95, 103219	10.2	9
221	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12,	6.4	5
220	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1868-1869	15.1	3
219	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Europace*, **2019**, 21, 796-802	3.9	7

218	International Triadin Knockout Syndrome Registry. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002419	5.2	20
217	Genetic risk stratification in cardiac arrhythmias. *Current Opinion in Cardiology*, **2018**, 33, 298-303	2.1	4
216	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. *Journal of the American College of Cardiology*, **2018**, 71, 1663-1671	15.1	76
215	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2018**, 15, 1394-1401	6.7	49
214	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Heart Rhythm*, **2018**, 15, 716-724	6.7	36
213	Information extraction from Italian medical reports: An ontology-driven approach. *International Journal of Medical Informatics*, **2018**, 111, 140-148	5.3	11
212	Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome. *Europace*, **2018**, 20, 234-242	3.9	15
211	Gene Therapy to Treat Cardiac Arrhythmias **2018**, 531-540		
210	Timothy Syndrome **2018**, 910-916		0
209	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart Rhythm*, **2018**, 15, 1457-1465	6.7	36
208	Catecholaminergic Polymorphic Ventricular Tachycardia. *Cardiac and Vascular Biology*, **2018**, 231-256	0.2	
207	The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. *European Archives of Psychiatry and Clinical Neuroscience*, **2018**, 268, 349-357	5.1	8
206	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. *Human Mutation*, **2018**, 39, 1835-1846	4.7	11
205	Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling. *BioMed Research International*, **2018**, 2018, 2806148	3	2
204	J-Wave Syndromes: Electrocardiographic and Clinical Aspects. *Cardiac Electrophysiology Clinics*, **2018**, 10, 355-369	1.4	8
203	Noninvasive quantification of blood potassium concentration from ECG in hemodialysis patients. *Scientific Reports*, **2017**, 7, 42492	4.9	16
202	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (). *Circulation Research*, **2017**, 121, 525-536	15.7	33
201	Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?. *Journal of the American College of Cardiology*, **2017**, 69, 248-249	15.1	1

200	MobiGuide: a personalized and patient-centric decision-support system and its evaluation in the atrial fibrillation and gestational diabetes domains. *User Modeling and User-Adapted Interaction*, **2017**, 27, 159-213	3.9	29
199	Assessment of a personalized and distributed patient guidance system. *International Journal of Medical Informatics*, **2017**, 101, 108-130	5.3	44
198	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. *Journal of the American College of Cardiology*, **2017**, 70, 3010-3015	15.1	41
197	Age of First Arrhythmic Event in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 Patients. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	39
196	Recurrent Neural Network Architectures for Event Extraction from Italian Medical Reports. *Lecture Notes in Computer Science*, **2017**, 198-202	0.9	4
195	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2016**, 7, e2393	9.8	37
194	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. *Circulation*, **2016**, 133, 622-30	16.7	138
193	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. *Journal of the American College of Cardiology*, **2016**, 67, 1053-1058	15.1	123
192	Interplay between Clinical Guidelines and Organizational Workflow Systems. Experience from the MobiGuide Project. *Methods of Information in Medicine*, **2016**, 55, 488-494	1.5	7
191	Multivariate Methods for Genetic Variants Selection and Risk Prediction in Cardiovascular Diseases. *Frontiers in Cardiovascular Medicine*, **2016**, 3, 17	5.4	7
190	Challenges in Molecular Diagnostics of Channelopathies in the Next-Generation Sequencing Era: Less Is More?. *Frontiers in Cardiovascular Medicine*, **2016**, 3, 29	5.4	4
189	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 937-43	2.7	14
188	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. *Journal of the American College of Cardiology*, **2016**, 68, 2540-2550	15.1	99
187	Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. *European Journal of Medical Genetics*, **2015**, 58, 332-5	2.6	11
186	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. *Current Opinion in Genetics and Development*, **2015**, 33, 17-24	4.9	17
185	Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. *British Journal of Cancer*, **2015**, 112, 1011-6	8.7	57
184	From decision to shared-decision: Introducing patients preferences into clinical decision analysis. *Artificial Intelligence in Medicine*, **2015**, 65, 19-28	7.4	21
183	Graphical representation of life paths to better convey results of decision models to patients. *Medical Decision Making*, **2015**, 35, 398-402	2.5	9

182	Combining Decision Support System-Generated Recommendations with Interactive Guideline Visualization for Better Informed Decisions. *Lecture Notes in Computer Science*, **2015**, 337-341	0.9	
181	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype. *Human Molecular Genetics*, **2014**, 23, 4875-86	5.6	52
180	Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload. *Journal of the American College of Cardiology*, **2014**, 63, 1569-79	15.1	37
179	Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. *Circulation*, **2014**, 129, 1092-103	16.7	242
178	Congenital Long QT Syndrome Type 3. *Cardiac Electrophysiology Clinics*, **2014**, 6, 705-713	1.4	3
177	Sodium Current Disorders. *Cardiac Electrophysiology Clinics*, **2014**, 6, 825-833	1.4	
176	Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. *Circulation*, **2014**, 129, 2673-81	16.7	64
175	Novel insight into the natural history of short QT syndrome. *Journal of the American College of Cardiology*, **2014**, 63, 1300-1308	15.1	147
174	Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT). *European Journal of Human Genetics*, **2014**, 22,	5.3	13
173	Timothy Syndrome **2014**, 953-957		1
172	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 499-519	2.5	31
171	Tyrosine kinase inhibitors and QTc intervals: A class effect.. *Journal of Clinical Oncology*, **2014**, 32, 2590-2590	2.2	1
170	Inheritable Phenotypes Associated With Altered Intracellular Calcium Regulation **2014**, 521-528		
169	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10312-7	11.5	42
168	Early phase telemedicine requirements elicitation in collaboration with medical practitioners **2013**,		5
167	Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2013**, 113, 142-52	15.7	37
166	CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2013**, 4, e843	9.8	92
165	Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. *Journal of Clinical Investigation*, **2013**, 123, 84-91	15.9	53

164	Supporting shared decision making within the MobiGuide project **2013**, 2013, 1175-84	0.7	7
163	Catecholaminergic Polymorphic Ventricular Tachycardia **2013**, 551-560		
162	L-Type Calcium Channel Disease **2013**, 209-217		1
161	Patient-tailored workflow patterns from clinical practice guidelines recommendations. *Studies in Health Technology and Informatics*, **2013**, 192, 392-6	0.5	6
160	Clinical and research data integration: the i2b2-FSM experience. *AMIA Summits on Translational Science Proceedings*, **2013**, 2013, 239-40	1.1	1
159	Genetics and Arrhythmias: Diagnostic and Prognostic Applications. *Revista Espanola De Cardiologia (English Ed)*, **2012**, 65, 278-286	0.7	
158	Genetics and arrhythmias: diagnostic and prognostic applications. *Revista Espanola De Cardiologia*, **2012**, 65, 278-86	1.5	31
157	Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14, 29	6.9	26
156	Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nature Reviews Cardiology*, **2012**, 9, 561-75	14.8	139
155	Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. *Journal of the American College of Cardiology*, **2012**, 59, 37-45	15.1	409
154	Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Trends in Cardiovascular Medicine*, **2012**, 22, 35-9	6.9	9
153	Genetic Mechanisms of Arrhythmia **2012**, 601-623		
152	Genetic testing of inherited arrhythmias. *Pediatric Cardiology*, **2012**, 33, 980-7	2.1	7
151	Risk Stratification in the Long QT Syndrome. *Cardiac Electrophysiology Clinics*, **2012**, 4, 53-60	1.4	1
150	Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. *Circulation Research*, **2012**, 110, 663-8	15.7	55
149	Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. *Circulation*, **2012**, 125, 2027-34	16.7	97
148	Genetics of ion-channel disorders. *Current Opinion in Cardiology*, **2012**, 27, 242-52	2.1	30
147	Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2012**, 126, 392-401	16.7	59

146	Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2011**, 8, 1601-5	6.7	6
145	Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. *Journal of the American College of Cardiology*, **2011**, 57, 51-9	15.1	205
144	Overexpression of CaMKII in RyR2R4496C+/- knock-in mice leads to altered intracellular Ca2+ handling and increased mortality. *Journal of the American College of Cardiology*, **2011**, 57, 469-79	15.1	28
143	Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. *Journal of the American College of Cardiology*, **2011**, 57, 941-50	15.1	84
142	Intracellular Calcium Handling and Inherited Arrhythmogenic Diseases **2011**, 387-408		
141	Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. *Journal of Molecular and Cellular Cardiology* , **2011**, 50, 214-22	5.8	95
140	RyRCa2+ leak limits cardiac Ca2+ window current overcoming the tonic effect of calmodulinin mice. *PLoS ONE*, **2011**, 6, e20863	3.7	10
139	Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. *Circulation Research*, **2011**, 108, 607-18	15.7	60
138	Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. *Circulation Research*, **2011**, 109, 291-5	15.7	84
137	R engine cell: integrating R into the i2b2 software infrastructure. *Journal of the American Medical Informatics Association: JAMIA*, **2011**, 18, 314-7	8.6	14
136	Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H288-99	5.2	38
135	Genetic and Molecular Basis of Arrhythmias **2011**, 65-86		1
134	Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. *Circulation Research*, **2010**, 106, 1374-83	15.7	61
133	In the RyR2(R4496C) mouse model of CPVT, adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. *Circulation Research*, **2010**, 107, 1483-9	15.7	76
132	Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. *Cardiovascular Research*, **2010**, 87, 50-9	9.9	74
131	Genetics for the Electrophysiologist: Take Home Messages for the Clinician. *Cardiac Electrophysiology Clinics*, **2010**, 2, 623-634	1.4	1
130	Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. *Journal of the American College of Cardiology*, **2010**, 55, 2745-52	15.1	143
129	When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias?. *Current Opinion in Cardiology*, **2010**, 25, 37-45	2.1	6

128	Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. *European Heart Journal*, **2009**, 30, 2241-8	9.5	128
127	High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". *Circulation*, **2009**, 119, 215-21	16.7	235
126	Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2009**, 104, 201-9, 12p following 209	15.7	114
125	Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 6-15	6.4	111
124	The genetics of cardiomyopathy: genotyping and genetic counseling. *Current Treatment Options in Cardiovascular Medicine*, **2009**, 11, 433-46	2.1	10
123	Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. *Journal of the American College of Cardiology*, **2009**, 54, 832-7	15.1	70
122	Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. *Heart Rhythm*, **2009**, 6, 1652-9	6.7	90
121	The heritable nature of the electrocardiogram: How far can population genetics go?. *Heart Rhythm*, **2009**, 6, 642-3	6.7	
120	Catecholaminergic polymorphic ventricular tachycardia. *Progress in Cardiovascular Diseases*, **2008**, 51, 23-30	8.5	130
119	Risk of death in the long QT syndrome when a sibling has died. *Heart Rhythm*, **2008**, 5, 831-6	6.7	55
118	Long-QT syndrome after age 40. *Circulation*, **2008**, 117, 2192-201	16.7	117
117	Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation*, **2008**, 117, 2184-91	16.7	229
116	Therapeutic strategies for long-QT syndrome: does the molecular substrate matter?. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 290-7	6.4	49
115	Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. *Circulation Research*, **2008**, 103, 298-306	15.7	110
114	L-type Calcium Channel Disease **2008**, 187-193		
113	Catecholaminergic Polymorphic Ventricular Tachycardia **2008**, 536-544		
112	Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2007**, 101, 1039-48	15.7	215
111	Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2007**, 4, 675-8	6.7	109

110	Just another Brugada syndrome mutation?. *Heart Rhythm*, **2007**, 4, 54-5	6.7	1
109	Long QT syndrome in adults. *Journal of the American College of Cardiology*, **2007**, 49, 329-37	15.1	311
108	Long QT syndrome and pregnancy. *Journal of the American College of Cardiology*, **2007**, 49, 1092-8	15.1	233
107	In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H56-65	5.2	20
106	Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 791-7	2.7	101
105	Venice Chart international consensus document on atrial fibrillation ablation. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 560-80	2.7	298
104	Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. *Circulation*, **2007**, 116, 1137-44	16.7	159
103	Magnetocardiographic findings and follow-up in an asymptomatic Brugada patient. Effects of Flecainide and of exercise tests. *International Congress Series*, **2007**, 1300, 459-462		3
102	Genetics of Inherited Arrhythmias **2007**, 502-513		
101	Computer simulation of wild-type and mutant human cardiac Na+ current. *Medical and Biological Engineering and Computing*, **2006**, 44, 35-44	3.1	9
100	Gene-specific therapy for inherited arrhythmogenic diseases **2006**, 110, 1-13		23
99	Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1249-54	27.4	216
98	Female predominance and transmission distortion in the long-QT syndrome. *New England Journal of Medicine*, **2006**, 355, 2744-51	59.2	63
97	Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. *Circulation Research*, **2006**, 99, 292-8	15.7	256
96	Letter regarding article by Coronel et al, "right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study". *Circulation*, **2006**, 113, e726; author reply 726-7	16.7	3
95	Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. *Circulation Research*, **2006**, 98, 1151-8	15.7	163
94	Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2006**, 114, 1012-9	16.7	169
93	Role of genetic analyses in cardiology: part I: mendelian diseases: cardiac channelopathies. *Circulation*, **2006**, 113, 1130-5	16.7	79

92	Brugada syndrome. *Orphanet Journal of Rare Diseases*, **2006**, 1, 35	4.2	28
91	Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. *Journal of Cardiovascular Medicine*, **2006**, 7, 250-6	1.9	25
90	Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice. *Yearbook of Cardiology*, **2006**, 2006, 456-457		
89	Brugada syndrome. *International Journal of Cardiology*, **2005**, 101, 173-8	3.2	21
88	Lateritic crusts and related soils in eastern Brazilian Amazonia. *Geoderma*, **2005**, 126, 225-239	6.7	37
87	Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. *JAMA - Journal of the American Medical Association*, **2005**, 294, 2975-80	27.4	346
86	A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. *Circulation Research*, **2005**, 96, 800-7	15.7	495
85	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. *Circulation*, **2005**, 112, 279-92; discussion 279-92	16.7	154
84	Intracellular calcium handling dysfunction and arrhythmogenesis: a new challenge for the electrophysiologist. *Circulation Research*, **2005**, 97, 1077-9	15.7	25
83	Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. *Circulation Research*, **2005**, 96, e77-82	15.7	204
82	Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. *Circulation*, **2005**, 112, 3680-7	16.7	267
81	Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. *Journal of Clinical Investigation*, **2005**, 115, 2033-8	15.9	70
80	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. *Circulation*, **2005**, 112, 279-92; discussion 279-92	16.7	12
79	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *European Heart Journal*, **2004**, 25, 437-45	9.5	53
78	Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation*, **2004**, 109, 1826-33	16.7	503
77	Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1341-4	27.4	445
76	Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17533-8	11.5	299
75	Transgenic models in cardiac arrhythmias: how close can we get to the bedside?. *Cardiovascular Research*, **2004**, 61, 206-7	9.9	1

74	Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. *Circulation Research*, **2004**, 94, 471-7	15.7	147
73	A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9137-42	11.5	264
72	Genetics of cardiac arrhythmias and sudden cardiac death. *Annals of the New York Academy of Sciences*, **2004**, 1015, 96-110	6.5	69
71	Policy statement: ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *Resuscitation*, **2004**, 60, 245-52	4	24
70	Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell*, **2004**, 119, 19-31	56.2	1182
69	Long QT Syndrome **2004**, 740-744		
68	Genetics of Long QT, Brugada, and Other Channelopathies **2004**, 462-470		8
67	Catecholaminergic Polymorphic Ventricular Tachycardia and Short-coupled Torsades de Pointes **2004**, 633-639		8
66	Risk stratification in the long-QT syndrome. *New England Journal of Medicine*, **2003**, 349, 908-9; author reply 908-9	59.2	7
65	Action potential changes due to Y1795H mutation in Brugada syndrome patients: a simulation study **2003**,		2
64	Risk stratification in the long-QT syndrome. *New England Journal of Medicine*, **2003**, 348, 1866-74	59.2	1090
63	Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management. *Journal of Interventional Cardiac Electrophysiology*, **2003**, 9, 93-101	2.4	25
62	A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 407-11	2.7	89
61	Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1149-53	2.7	63
60	How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1120-1	2.7	96
59	Flecainide test in Brugada syndrome: a reproducible but risky tool. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 338-41	1.6	79
58	Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. *Journal of the American College of Cardiology*, **2003**, 41, 633-42	15.1	179
57	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *Journal of the American College of Cardiology*, **2003**, 42, 103-9	15.1	224

56	FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. *Cell*, **2003**, 113, 829-40	56.2	589
55	Markovian model for wild-type and mutant (Y1795C and Y1795H) human cardiac Na/sup +/ channel **2003**,		2
54	Cardiac sodium channel diseases. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 439-44	5.9	24
53	The Long QT Syndrome. *Contemporary Cardiology*, **2003**, 169-185	0.1	
52	Programmed electrical stimulation in Brugada syndrome: how reproducible are the results?. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 880-7	2.7	47
51	Romano-Ward and other congenital long QT syndromes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 19-23	3.9	1
50	Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 89-92	3.9	20
49	Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2002**, 106, 69-74	16.7	937
48	Torsade de pointes. *Emergency Medicine Journal*, **2002**, 19, 485-6	1.5	6
47	Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. *European Heart Journal*, **2002**, 23, 975-83	9.5	90
46	Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation*, **2002**, 105, 1342-7	16.7	805
45	Genetics of ventricular tachycardia. *Current Opinion in Cardiology*, **2002**, 17, 222-8	2.1	9
44	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-1209	15.9	162
43	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-9	15.9	67
42	Will the Spectrum of Ion Channel Diseases Increase Further in the Near Future? **2002**, 212-218		
41	Catecholaminergic Polymorphic Ventricular Tachycardia: Another Inherited Arrhythmia? **2002**, 187-190		
40	Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 455-61	2.7	74
39	Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. *Journal of Biological Chemistry*, **2001**, 276, 30623-30	5.4	151

38	Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. *Circulation Research*, **2001**, 88, 740-5	15.7	105
37	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*, **2001**, 103, 89-95	16.7	1363
36	Clinical implications for affected parents and siblings of probands with long-QT syndrome. *Circulation*, **2001**, 104, 557-62	16.7	61
35	Molecular diagnosis in a child with sudden infant death syndrome. *Lancet, The*, **2001**, 358, 1342-3	40	135
34	Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2001**, 103, 196-200	16.7	1101
33	Concealed arrhythmogenic syndromes: the hidden substrate of idiopathic ventricular fibrillation?. *Cardiovascular Research*, **2001**, 50, 218-23	9.9	28
32	Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 691-6	2.7	280
31	Significance of QT dispersion in the long QT syndrome. *Progress in Cardiovascular Diseases*, **2000**, 42, 345-50	8.5	19
30	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. *American Journal of Cardiology*, **2000**, 85, 457-61	3	61
29	Mechanisms of I(Ks) suppression in LQT1 mutants. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H3003-11	5.2	53
28	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H1748-56	5.2	74
27	Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*, **2000**, 101, 616-23	16.7	646
26	Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. *Circulation*, **2000**, 102, 2849-55	16.7	352
25	A molecular link between the sudden infant death syndrome and the long-QT syndrome. *New England Journal of Medicine*, **2000**, 343, 262-7	59.2	296
24	Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. *Circulation*, **2000**, 102, 2509-15	16.7	420
23	The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. *Circulation*, **2000**, 102, 945-7	16.7	211
22	Brugada syndrome and sudden cardiac death in children. *Lancet, The*, **2000**, 355, 808-9	40	198
21	Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome. *Circulation*, **1999**, 99, 1344-7	16.7	65

20	Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. *Human Molecular Genetics*, **1999**, 8, 1499-507	5.6	149
19	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. *American Journal of Cardiology*, **1999**, 84, 876-9	3	186
18	Low penetrance in the long-QT syndrome: clinical impact. *Circulation*, **1999**, 99, 529-33	16.7	650
17	Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *New England Journal of Medicine*, **1998**, 339, 960-5	59.2	628
16	A recessive variant of the Romano-Ward long-QT syndrome?. *Circulation*, **1998**, 97, 2420-5	16.7	120
15	Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation*, **1998**, 97, 2237-44	16.7	377
14	Recruitment of the TATA-binding protein to the HIV-1 promoter is a limiting step for Tat transactivation. *Aids*, **1998**, 12, 1957-64	3.5	19
13	Molecular biology of the long QT syndrome: impact on management. *PACE - Pacing and Clinical Electrophysiology*, **1997**, 20, 2052-7	1.6	32
12	Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome. *Circulation*, **1997**, 96, 3006-12	16.7	114
11	Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. *Circulation Research*, **1996**, 78, 1009-15	15.7	115
10	Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. *Journal of the American College of Cardiology*, **1995**, 25, 1609-14	15.1	39
9	Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. *Circulation*, **1995**, 92, 3381-6	16.7	532
8	Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. *Circulation*, **1994**, 89, 1681-9	16.7	321
7	Torsade de pointes. Mechanisms and management. *Drugs*, **1994**, 47, 51-65	12.1	100
6	Cardiac receptor activation and arrhythmogenesis. *European Heart Journal*, **1993**, 14 Suppl E, 20-6	9.5	61
5	Pathogenesis and therapy of the idiopathic long QT syndrome. *Annals of the New York Academy of Sciences*, **1992**, 644, 112-41	6.5	33
4	Electrophysiologic mechanisms involved in the development of torsades de pointes. *Cardiovascular Drugs and Therapy*, **1991**, 5, 203-12	3.9	16
3	Early afterdepolarizations induced in vivo by reperfusion of ischemic myocardium. A possible mechanism for reperfusion arrhythmias. *Circulation*, **1990**, 81, 1911-20	16.7	59

List of Publications